Advanced Filters
noise
Found 64,776 clinical trials
C Chloe Najac, PhD, MSc

Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI

In this study, the invesigators look at how a new MRI technique (called amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST)) can improve treatment for brain tumors through early detection of tumor progression after radiotherapy and/or chemotherapy treatment. An issue with the current treatment for patients with a …

18 years of age All Phase N/A
A Ariana Satcher

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.

18 years of age All Phase 2
S SHEILA M SCHINDLER-IVENS, PhD

CUped: An Approach to Motor Recovery Post-Stroke, Not Compensation

The goal of lower limb rehabilitation after stroke is recovery of independent walking at home and in the community. Few stroke survivors achieve this goal. Suboptimal outcomes are due to the serious and intransigent nature of movement impairments caused by stroke and the scarcity of feasible and effective therapies that …

18 - 100 years of age All Phase N/A
M Maya Frank Wolf, Prof.

Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo

Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.

18 years of age Female Phase N/A
J Jian Fengzeng

The Therapeutic Effect of Thalidomide in Syringomyelia

Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared …

18 - 80 years of age All Phase 2
M Michael Roth, MD

Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention

The goal of this research study is to learn about the effects of the RISE-YA intervention on cancer-related fatigue in young adults who are brain cancer survivors.

18 - 39 years of age All Phase 2
G Grace Mirembe, MBChB, MMed

Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered, dose-consistent vaccination schedule. Participants randomized to receive vaccines will get either dose-consistent injections of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV …

18 - 50 years of age All Phase 1
G Gerhard Poelzl, Prof. Dr.

Efficacy of an Assisted Therapy Optimizing Module to Improve Physician Adherence

Heart failure patients within the HM programme

18 years of age All Phase N/A
T Tian Hua

Evaluation of the Effect of SURGICEL® Powder in TKA

The study subjects are patients in our hospital's orthopedics department undergoing unilateral primary total knee arthroplasty (TKA) due to primary osteoarthritis. Through a prospective, parallel randomized controlled study, 112 participants will be divided into two groups: the SURGICEL® Powder group and the non-use group. The study will compare the total …

years of age All Phase 4
Y Yana Zhang, Doctor

the Efficacy and Safety of Ondansetron Oral Soluble Pellicles

The name of this prospective study is a multicenter, open-label, randomized controlled clinical study of the efficacy and safety of Ondansetron Oral Soluble Pellicles for the prevention of delayed nausea and vomiting induced by highly emetogenic chemotherapy.

18 years of age All Phase 3

Simplify language using AI